The CEO of Xenon is Exercising Options

By Carrie Williams

Today, the CEO of Xenon, Simon Pimstone, exercised options of Xenon for $38.79K. The options were close to expired and Simon Pimstone retained stocks.

Following this transaction Simon Pimstone’s holding in the company was increased by 4.39% to a total of $1.15 million. Following Simon Pimstone’s last XENE Buy transaction on August 14, 2017, the stock climbed by 2.2%.

The company has a one-year high of $9.95 and a one-year low of $2.10. Currently, Xenon has an average volume of 102.4K.

Starting in December 2014, XENE received 48 Buy ratings in a row. Six different firms, including Canaccord Genuity and Cantor Fitzgerald, currently also have a Buy rating on the stock.

Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Xenon Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in discovering and developing a pipeline of differentiated therapeutics.